MoonLake Immunotherapeutics (MLTX) Profit After Tax (2021 - 2026)

MoonLake Immunotherapeutics' Profit After Tax history runs 6 years deep, the most recent figure standing at -$70.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 75.22% year-over-year to -$70.0 million; the TTM figure through Mar 2026 stood at -$265.9 million (down 84.34% YoY), while the FY2025 annual figure was -$234.8 million, down 101.75% from the prior year.
• Profit After Tax for Q1 2026 stood at -$70.0 million, roughly flat from -$69.9 million in the prior quarter.
• The five-year high for Profit After Tax was -$6.6 million in Q3 2023, with the low at -$70.0 million in Q1 2026.
• The 5-year median for Profit After Tax is -$17.4 million (2022), against an average of -$31.1 million.
• Peak annual rise in Profit After Tax reached 69.4% in 2022, while the deepest fall reached 4415.6% in 2022.
• MoonLake Immunotherapeutics' Profit After Tax stood at -$16.5 million in 2022, then jumped by 48.9% to -$8.4 million in 2023, then slumped by 416.24% to -$43.4 million in 2024, then slumped by 60.93% to -$69.9 million in 2025, then dropped by 0.11% to -$70.0 million in 2026.
• Business Quant data shows MLTX's Profit After Tax at -$70.0 million in Q1 2026, -$69.9 million in Q4 2025, and -$70.0 million in Q3 2025.